{"id":48566,"date":"2023-04-03T14:02:03","date_gmt":"2023-04-03T12:02:03","guid":{"rendered":"https:\/\/test.lab.cor2ed.com\/cms\/?post_type=experts&p=48566"},"modified":"2023-10-16T13:02:31","modified_gmt":"2023-10-16T11:02:31","slug":"prof-frederique-penault-llorca-2","status":"publish","type":"experts","link":"https:\/\/test.lab.cor2ed.com\/cms\/experts\/prof-frederique-penault-llorca-2\/","title":{"rendered":"Prof. Fr\u00e9d\u00e9rique PENAULT-LLORCA"},"content":{"rendered":"

Fr\u00e9d\u00e9rique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Universit\u00e9 d\u2019Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Fr\u00e9d\u00e9rique PENAULT-LLORCA is currently professor of pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin. She serves as vice-president of the UNICANCER group and chairs of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, with her main areas of expertise being female cancers. She co-chairs the French breast cancer guidelines of Nice-St Paul. Fr\u00e9d\u00e9rique PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, lung, digestive tract, prostate and thyroid cancer in relation to response to targeted therapies and immunotherapies. Fr\u00e9d\u00e9rique PENAULT-LLORCA has participated to more than 469 peer-reviewed publications and several books on female cancers and pathologic testing methods and issues.<\/span><\/p>\n","protected":false},"author":{"id":1337,"first_name":"Thais","last_name":"Miranda","nickname":"thais.miranda","email":"thais.miranda@cor2ed.com"},"featured_media":134454,"menu_order":0,"template":"","groups":[24],"class_list":["post-48566","experts","type-experts","status-publish","has-post-thumbnail","hentry","groups-members"],"expert_info_prefix":"Prof.","expert_info_first-name":"Fr\u00e9d\u00e9rique ","expert_info_last-name":"PENAULT-LLORCA","expert_info_institution":"University of Clermont-Ferrand","expert_info_country":"FR","expert_info_specialization":"Pathologist","expert_info_map-code":"eu_113","expert_info_disclosures":"

AstraZeneca, Daiichi Sankyo, Roche, Seagreen, Novartis, Lilly, Gilead, Pfizer, MSD, BMS, Janssen<\/span><\/p>","expert_info_linkedin":"","expert_info_twitter":"","expert_info_instagram":"","expert_info_facebook":"","_links":{"self":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/48566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts"}],"about":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/types\/experts"}],"version-history":[{"count":1,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/48566\/revisions"}],"predecessor-version":[{"id":48567,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/experts\/48566\/revisions\/48567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/media\/134454"}],"wp:attachment":[{"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/media?parent=48566"}],"wp:term":[{"taxonomy":"groups","embeddable":true,"href":"https:\/\/test.lab.cor2ed.com\/cms\/wp-json\/wp\/v2\/groups?post=48566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}